Larimar Therapeutics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2005-01-01
- Employees
- 42
- Market Cap
- $514.2M
- Website
- http://larimartx.com
Clinical Trials
7
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06681766
- Locations
- 🇺🇸
Uncommon Cures, Chevy Chase, Maryland, United States
An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia
- Conditions
- Friedreich Ataxia
- First Posted Date
- 2024-06-06
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 75
- Registration Number
- NCT06447025
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸Fixel Institute for Neurological Disease, University of Florida Health, Gainesville, Florida, United States
🇺🇸Morsani Center for Advanced Health Care, University of South Florida Health, Tampa, Florida, United States
A Double-Blind, Placebo-Controlled, Dose Exploration Study of CTI-1601 in Adult Subjects With Friedreich's Ataxia
- First Posted Date
- 2022-10-14
- Last Posted Date
- 2024-11-29
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 28
- Registration Number
- NCT05579691
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Determine Range of Tissue Frataxin Concentrations and Other Potential Biomarkers
- Conditions
- Friedreich AtaxiaHealthy Volunteers
- First Posted Date
- 2021-08-31
- Last Posted Date
- 2022-02-24
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT05028764
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
Multiple Ascending Dose Study of CTI-1601 Versus Placebo in Subjects With Friedreich's Ataxia
- Conditions
- Friedreich Ataxia
- First Posted Date
- 2020-08-19
- Last Posted Date
- 2021-06-30
- Lead Sponsor
- Larimar Therapeutics, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT04519567
- Locations
- 🇺🇸
Clinilabs Drug Development Corporation, Eatontown, New Jersey, United States
- Prev
- 1
- 2
- Next
News
Larimar Therapeutics Advances Nomlabofusp Clinical Trials for Friedreich's Ataxia
Larimar Therapeutics is progressing with clinical trials of nomlabofusp, targeting adolescent patients with Friedreich's ataxia, with potential data expected in mid-2025.
FDA's START Program Selects First Rare Disease Therapies for Accelerated Development
• The FDA's START program, designed to expedite rare disease therapy development, has chosen its first candidates for enhanced guidance and support. • Denali Therapeutics' DNL12 for mucopolysaccharidosis IIIA, Neurogene's NGN-401 for Rett syndrome, and Larimar Therapeutics' nomlabofusp for Friedreich's ataxia are among the selected therapies. • Grace Science's GS-100 gene therapy for NGLY1 deficiency is also included, marking a significant step forward in addressing this life-threatening condition with no approved treatments. • The START program aims to provide comprehensive support in clinical trial design and data generation, facilitating efficient development of potentially life-saving therapies.
Larimar Therapeutics' Nomlabofusp Shows Promise in Friedreich's Ataxia Trials
Larimar Therapeutics' nomlabofusp demonstrates positive initial data in a long-term open label extension study for Friedreich's Ataxia, showing increased frataxin levels.
Larimar Therapeutics' Nomlabofusp Shows Promise in Friedreich's Ataxia Studies
Nomlabofusp treatment demonstrates modification of gene expression and lipid profiles, alongside increased frataxin (FXN) levels in Friedreich's ataxia (FA) patients.
Larimar Therapeutics Advances Nomlabofusp for Friedreich's Ataxia; Reports Q3 2024 Results
Larimar Therapeutics reported a Q3 2024 net loss of $15.5 million, with a strong cash position of $203.7 million, expected to last into 2026.
Larimar Therapeutics Advances Nomlabofusp for Friedreich's Ataxia Treatment
Larimar Therapeutics anticipates a mid-December update on its nomlabofusp program, including safety, pharmacokinetic, and frataxin data from the ongoing open-label extension study.
Larimar Therapeutics' Nomlabofusp Shows Promise in Friedreich's Ataxia Treatment
Larimar Therapeutics presented positive early clinical trial results for nomlabofusp (CTI-1601) in Friedreich's ataxia (FRDA) patients, highlighting its potential to address frataxin deficiency.
Leading Biotech Companies Converge at Mitochondria-Targeted Drug Development Summit to Advance Therapeutic Pipeline
• Industry leaders from Stealth BioTherapeutics, Cohbar, and GenSight Biologics will gather at the exclusive Mitochondria-Targeted Drug Development Digital Summit to share breakthrough research developments. • The summit will showcase innovative approaches including Mitokinin's PINK1 activation for Parkinson's disease and Larimar Therapeutics' CTI-1601 protein replacement therapy for Friedreich's Ataxia. • Over 80 key industry experts will participate in 20+ hours of content and workshops, focusing on advancing therapeutics for mitochondrial and age-related diseases.